{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:59:31Z","timestamp":1790290771039,"version":"4.1.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>The effects of various treatments on Graves\u2019 ophthalmopathy (GO) have been studied. As monoclonal antibodies (mAbs) have been proposed for the treatment of moderate to severe GO, direct comparisons between different mAbs are lacking.We therefore conducted this meta-analysis to objectively compare the efficacy and safety of intravenous mAbs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To identify eligible trials, references published before September 2022 were electronically searched in PubMed, Web of Science, Pubmed, Embase,Cochrane Library, CBM, CNKI,Wan-Fang and ICTRP databases.The Newcastle-Ottawa scale (NOS) and the Cochrane Risk of Bias Assessment Tool were used to assess the risk of bias of the original studies.The primary and secondary outcomes were the response and inactivation rates, with the secondary outcomes being the clinical activity score (CAS),the improvement of proptosis and diplopia improvement,and the adverse event rate. Publication bias was evaluated, along with subgroup and sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 12 trials with 448 patients were included. The meta-analysis showed that TCZ (tocilizumab) was most likely to be the best treatment in terms of response according to indirect contrast, followed by TMB (teprotumumab) and RTX (rituximab).TCZ, followed by TMB and RTX, was also most likely to be the best treatment in terms of reducing proptosis. In terms of improving diplopia, TMB was most likely to be the best treatment, followed by TCZ and RTX.TCZ was the highest probability of safety, followed by RTX and TMB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on the best available evidence,TCZ should be the preferred treatment for moderate to severe GO.In the absence of head-to-head trials,indirect comparisons of treatments are routinely used to estimate the effectiveness of the treatments of interest. In addition,the optimal dose and potential mechanism of action of monoclonal antibodies remain to be established,and it is encouraging that the treatment paradigm for GO may change in the future.<\/jats:p><jats:p>This study was designed in accordance with the Preferred Reporting Items for conducting Systematic Reviews and Meta-Analyses (PRISMA)(27).<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>http:\/\/www.crd.york.ac.uk\/prospero<\/jats:uri>, identifier CRD42023398170.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1160936","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T05:18:12Z","timestamp":1684819092000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves\u2019ophthalmopathy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001292","article-title":"Bony orbital volume expansion in thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves\u2019 ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu","year":"2014","journal-title":"Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Clinical practice","volume":"360","author":"Bartalena","year":"2009","journal-title":"Graves\u2019 ophthalmopathy N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.21.2.0393","article-title":"Management of graves\u2019ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2013.12.007","article-title":"Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients","volume":"49","author":"Son","year":"2014","journal-title":"Can J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2013.12.002","article-title":"Assessing quality of life in Taiwanese patients with graves\u2019 ophthalmopathy","volume":"114","author":"Lin","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in graves\u2019 disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European thyroid Association\/European group on graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480491","article-title":"Multi-center study on the characteristics and treatment strategies of patients with graves\u2019 orbitopathy: the first European group on graves\u2019 orbitopathy experience","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-38-5-913","article-title":"The use of ACTH and cortisone in the treatment and in the differential diagnosis of malignant exophthalmos","volume":"38","author":"Kinsell","year":"1953","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0801880","article-title":"Clinical practice. graves\u2019 disease","volume":"358","author":"Brent","year":"2008","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in graves\u2019 ophthalmopathy","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0158","article-title":"Methylprednisolone and hepatotoxicity in graves\u2019 ophthalmopathy","volume":"22","author":"Wichary","year":"2012","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0267","article-title":"Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in graves\u2019 ophthalmopathy","volume":"17","author":"Le Moli","year":"2007","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy","volume":"80","author":"Kauppinen-M\u00e4kelin","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active graves\u2019 ophthalmopathy successfully treated with b lymphocyte depletion","volume":"16","author":"El Fassi","year":"2006","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital b-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B29","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses - 2008","author":"Wells","year":"2014"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of b-cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with graves\u2019 orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"Deltour","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119845224","article-title":"The effects of rituximab on graves\u2019orbitopathy: a retrospective study of 14 patients","volume":"30","author":"Eid","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-Severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040706","article-title":"Steroid-resistant graves\u2019 orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience","volume":"10","author":"P\u00e9rez-Moreiras","year":"2021","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory graves\u2019 orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant graves\u2019 orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0265-2","article-title":"The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy","volume":"33","author":"Smith","year":"2019","journal-title":"Eye (Lond)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12317","article-title":"Meta-analysis of methylprednisolone pulse therapy for graves\u2019 ophthalmopathy","volume":"42","author":"Gao","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for graves\u2019 ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for graves\u2019 orbitopathy: a questionnaire survey among members of the European thyroid association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.579","article-title":"Intravenous immunoglobulin versus corticosteroid in treatment of graves\u2019 ophthalmopathy","volume":"7","author":"Baschieri","year":"1997","journal-title":"Thyroid"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in graves\u2019 ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1453078","article-title":"Low-dose rituximab for active moderate to severe graves\u2019 orbitopathy resistant to conventional treatment","volume":"27","author":"Du Pasquier-Fediaevsky","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"B49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800555105","article-title":"Maintenance of the plasma cell pool is independent of memory b cells","volume":"105","author":"Ahuja","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103070","article-title":"Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review","volume":"9","author":"Atienza-Mateo","year":"2020","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/archopthalmol.2011.1215","article-title":"Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action","volume":"130","author":"Salvi","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.8.8768861","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with graves\u2019 disease","volume":"81","author":"Salvi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ni1117-1271b","article-title":"Corrigendum: IL-6 as a keystone cytokine in health and disease","volume":"18","author":"Hunter","year":"2017","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283499446","article-title":"The pathophysiology of thyroid eye disease: implications for immunotherapy","volume":"22","author":"Douglas","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/pr.109.002469","article-title":"Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases","volume":"62","author":"Smith","year":"2010","journal-title":"Pharmacol Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"Graves\u2019 disease: introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"W\u00e9meau","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00167","article-title":"Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy","volume":"7","author":"Smith","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2019.151902","article-title":"Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy","volume":"225","author":"Paik","year":"2020","journal-title":"Immunobiology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e220303","DOI":"10.1530\/EC-22-0303","article-title":"Rituximab in the treatment of graves\u2019 orbitopathy: latest updates and perspectives","volume":"11","author":"Supronik","year":"2022","journal-title":"Endocr Connect"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1804","article-title":"Potential utility of rituximab for graves\u2019 orbitopathy","volume":"98","author":"Salvi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1347e52","DOI":"10.1158\/1078-0432.CCR-12-0928","article-title":"Molecular pathways: hepatitis c virus, CXCL10, and the inflammatory road to liver cancer","volume":"19","author":"Brownell","year":"2013","journal-title":"Clin Canc Res: Offl J Am Assoc Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.04.022","article-title":"Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10","volume":"55","author":"Antonelli","year":"2011","journal-title":"Cytokine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2004.06.016","article-title":"Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old","volume":"39","author":"Spinelli","year":"2004","journal-title":"J Pediatr Surg"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"Smoke and autoimmunity: the fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz289","article-title":"Th1 chemokines in autoimmune endocrine disorders","volume":"105","author":"Fallahi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3011","article-title":"Graves\u2019 hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease","volume":"99","author":"Rapoport","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1055\/a-0725-9297","article-title":"Reflections on thyroid autoimmunity: a personal overview from the past into the future","volume":"50","author":"Rapoport","year":"2018","journal-title":"Horm Metab Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001052","article-title":"Thyrotropin receptor antibodies-an overview","volume":"34","author":"Kotwal","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.653627","article-title":"Insulin-like growth factor pathway and the thyroid","volume":"12","author":"Smith","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0283-1","article-title":"Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy","volume":"48","author":"Savino","year":"2015","journal-title":"Endocrine"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.5981","article-title":"Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab","volume":"55","author":"Komura","year":"2016","journal-title":"Intern Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-016-1108-9","article-title":"Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials","volume":"18","author":"Teitsma","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1160936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T05:18:16Z","timestamp":1684819096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1160936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":85,"alternative-id":["10.3389\/fendo.2023.1160936"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1160936","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"article-number":"1160936"}}